# Frank Walsh

> Frank Walsh is a funding round investor at Enterprise Equity backing Medical and Big Data. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Enterprise Equity](https://shizune.co/investors/profile/enterprise-equity-limited)
- Location: Dundalk, Ireland
- Total investments: 4
- Last investment: Apr 2020
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/frwalsh/

Frank Walsh is a funding round investor at Enterprise Equity in Dundalk focused on Medical and Big Data. Frank Walsh, BComm, Dip.Comp. Sc., NASD Series 7, joined Enterprise Equity in 2006.Frank has worked in investment finance in both the United States and Ireland for over 15 years. His direct experience includes investment banking, equity research, venture capital, and joint venture development. Frank has helped numerous technology companiesraise both public and private capital as part of Initial Public Offerings, Secondaries, PIPE’s, and Venture Fundings.In addition to his international Corporate Finance experience, Frank worked directly with a number of Irish start-ups to help them maximise their business potential, drive company growth, and importantly, to do so in a manner than enhanced the company’s ability to attract external investment. Finally, Frank was a founding director of two companies since his return to Ireland, both of which operated successfully and were ultimately sold.Frank is based at our Cork Office.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 25% |
| Big Data | 1 | 25% |
| Health Care | 1 | 25% |
| Life Science | 1 | 25% |
| Biotechnology | 1 | 25% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 1 | 25% |
| Convertible Note | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Metabolomic Diagnostics | Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy. | $541.6K | Convertible Note | Apr 28, 2020 |  |
| Metabolomic Diagnostics | Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy. | $1.1M |  | Apr 06, 2018 |  |
| Metabolomic Diagnostics | Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy. | $1.9M |  | Jun 16, 2016 |  |
| Metabolomic Diagnostics | Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy. | $686K |  | Dec 08, 2014 |  |

4 of 4 investments shown.

## Co-investors
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund, 2 deals together
- [Diagnostics Polymers](https://shizune.co/investors/profile/diagnostics-polymers) — VC Fund, 1 deal together
- [RebelBio](https://shizune.co/investors/profile/rebelbio-eu) — VC Fund, 1 deal together
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund, 1 deal together

## About Enterprise Equity

VC Fund · Dundalk, Ireland

Enterprise Equity (or EEVC) is an excellent for providing capital to early stage and expanding business throughout Ireland.

5 contacts available at Enterprise Equity.

| Name | Title | Profile |
| --- | --- | --- |
| Frank Walsh | Partner and Director | https://shizune.co/investors/profile/frank-walsh |
| Hiroshi Okamoto | Venture Partner | https://shizune.co/investors/profile/hiroshi-okamoto |
| Regina Lane | Accounts and Compliance Manager | https://shizune.co/investors/profile/regina-lane |
| Rory Hynes | Venture Partner | https://shizune.co/investors/profile/rory-hynes |
| Akira Sato | Venture Partner | https://shizune.co/investors/profile/akira-sato |

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Frank Walsh invest in?

Frank Walsh invests primarily in Medical, Big Data and Health Care startups, most often at Funding Round and Convertible Note stage. Most of the 4 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Frank Walsh last invest?

The most recent investment recorded for Frank Walsh closed in Apr 2020. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co